IP Library Granted Patent US 11,385,246
Granted Patent B2
US 11,385,246 · App. 16/537,075 · Granted Jul 12, 2022

Antibodies to paliperidone and use thereof

Inventors: Eric Hryhorenko (Hilton, NY); Banumathi Sankaran (Pittsford, NY); Thomas R. DeCory (Pittsford, NY); Theresa Tubbs (Rochester, NY); Linda Colt (Rochester, NY); Maarten Vliegen (Rijkevorsel, BE); Pieter Rik Haspeslagh (Halen, BE)
Assignee: Saladax Biomedical Inc.
G01N33/9413C07K16/44G01N33/9406C07K2317/33C07K2317/56C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,385,246
App. No.
16/537,075
Granted
Jul 12, 2022
Kind
B2
Abstract

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.

Claims (15)

1. An isolated antibody, which specifically binds to paliperidone comprising a light chain variable region comprising CDR1, CDR2 and CDR3 of SEQ ID NO:7, and a heavy chain variable region comprising CDR1, CDR2 and CDR3 of SEQ ID NO:8, wherein the light chain CDR1 sequence comprises amino acid residues 44 to 60 of SEQ ID NO:7; the light chain CDR2 sequence comprises amino acid residues 76 to 82 of SEQ ID NO:7; the light chain CDR3 sequence comprises amino acid residues 115 to 123 of SEQ ID NO:7; the heavy chain CDR1 sequence comprises amino acid residues 45 to 54 of SEQ ID NO:8; the heavy chain CDR2 sequence comprises amino acid residues 69 to 85 of SEQ ID NO:8; and the heavy chain CDR3 sequence comprises amino acid residues 118 to 122 of SEQ ID NO:8.

2. The isolated antibody of claim 1 , wherein the antibody fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

3. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.

4. An assay kit comprising the isolated antibody of claim 1 .

5. An assay device comprising the isolated antibody of claim 1 .

6. The assay device of claim 5 , wherein the device is a lateral flow assay device.

7. A method of detecting paliperidone in a sample, the method comprising:

(i) contacting a sample with the antibody of claim 1 labeled with a detectable marker, wherein the labeled antibody, and paliperidone present in the sample form a labeled complex; and

(ii) detecting the labeled complex, thereby detecting paliperidone in the sample.

8. A competitive immunoassay method for detecting paliperidone in a sample, the method comprising:

(i) contacting a sample with the antibody of claim 1 , and with paliperidone or a competitive binding partner of paliperidone, wherein one of (a) the antibody, and (b) the paliperidone or the competitive binding partner, is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or the competitive binding partner for binding to the antibody to form a complex; and

(ii) detecting the amount of the detectable marker to detect sample paliperidone.

9. The method of claim 8 , wherein the paliperidone or the competitive binding partner is labeled with the detectable marker.

10. The method of claim 8 , wherein the antibody is labeled with the detectable marker.

11. The method of claim 8 , wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: JANSSEN PHARMACEUTICA NV
To: SALADAX BIOMEDICAL INC.
Reel/Frame 059137/0641 →
Continuity (4)
Continuation 15287301 · Oct 6, 2016
Continuation 13971416 · Aug 20, 2013
Provisional Application 61691692 · Aug 21, 2012
Related Publication 20190391169A1 · Dec 26, 2019